Literature DB >> 11990871

Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis.

O R Hommes1, H L Weiner.   

Abstract

In November 2000, a questionnaire was sent to 702 multiple sclerosis (MS) centers. Data on the institute, treating neurologists, number of MS patients under care, and the number of patients treated with immunosuppressive treatments were collected. The results indicate that overall, around 10% of MS patients are treated with one of four drugs: azathioprine, cyclophosphamide, methotrexate, and mitoxantrone. Azathioprine was most frequently used. More than 30% of MS patients in France are treated with immunosuppressive drugs. In some other countries, these treatments are hardly prescribed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11990871     DOI: 10.1191/1352458502ms791oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

2.  Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

Authors:  Fereshteh Ashtari; Mohammad Reza Savoj
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

3.  The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.

Authors:  Emanuele D'Amico; Carmela Leone; Giusi Graziano; Maria Pia Amato; Roberto Bergamaschi; Paola Cavalla; Gabriella Coniglio; Giancarlo Di Battista; Maria Teresa Ferrò; Franco Granella; Enrico Granieri; Alessandra Lugaresi; Giacomo Lus; Enrico Millefiorini; Carlo Pozzilli; Gioacchino Tedeschi; Mario Zappia; Giancarlo Comi; Maria Trojano; Vito Lepore; Francesco Patti
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.